CX-614 is the company code given to an ampakine research chemical developed by Cortex Pharmaceuticals. It is the third type of ampakine released by the pharmaceutical company right after cx-516 and cx-546. CX614 has been the subject of numerous clinical studies that are exploring its potential as treatment for neurological disorders such as Alzheimer’s disease and Parkinson’s disease.
As an ampakine, it naturally caught the attention of online communities of nootropic users who were interested in its cognitive enhancing capabilities. Ampakines are considered to be one of the more effective and potent cognitive enhancers available today. The action of ampakines involves the modulation of AMPA and NMDA glutamatergic receptors in the brain. Increased receptor activity is thought to result in enhanced cognitive processes in the brain.
Cortex Pharmaceutical is recognized as one of the world’s leading researchers in the field of neurological and cognitive medicine. It has spearheaded several significant researches and has developed several experimental compounds for cognitive enhancement and sometimes in collaboration with established pharmaceutical giants such as Shire Plc and Servier Laboratories. Incidentally, Shire is the developer of the Adderall, the well-known drug prescribed for attention deficit hyperactivity disorder (ADHD).
It is generally believed that cx-614 is an improvement from cx-546, which had some inherent weaknesses in terms of bioavailability, potency, and half-life. Most of the studies on cx-614 focus on its potential as treatment for neurodegenerative diseases because of its potent neuroprotective abilities.
The structure of cx-614 is similar to its predecessor, the cx-546 and this means that their effects are very likely similar as well. CX-516 and cx-546 both exhibited reasonably good potential as cognitive enhancers when it was tested on laboratory mice, but turned out to be not as effective when it was tested on humans. The weaknesses of the two previous ampakines were apparently their poor oral bioavailability and short half-life. There currently are no studies that say whether or not cx-614 has overcome the weaknesses of its predecessors.
Assuming that these weaknesses were already addressed with the cx-614, it would mean that this ampakine has to be a significantly better cognitive enhancer than cx-516 and cx-546. Tests on lab animals show that the administration of the two ampakines improved the memory, learning abilities, and analytical skill of the laboratory mice. These improvements failed to be recognized with the human subjects with the two previous CX ampakines, but may actually be achieved with the cx-614.
While it is nice to make such assumptions about cx-614, it can never be definitive until more studies and trials are conducted on the ampakine. If indeed cx-614 were a better ampakine and cognitive enhancer than the two previous ampakines from Cortex Pharmaceuticals, it would have at least been made public by now. However, Cortex has focused its attention on a new ampakine, the cx-717, which leads one to wonder if cx-614 is indeed effective. One study also revealed that cx-614 also has a weakness. The study suggests that subjects were prone to develop a tolerance for cx-614 at a fast rate, which means that long term supplementation with it may not be viable.
- It shows very good potential as a cognitive enhancer.
- It apparently has strong neuroprotective properties.
- It may lead to the development of more effective treatments for neurological and psychological conditions.
- There is not much data available on the ampakine.
- Genuine cx-614 is extremely difficult to get a hold of.
- It may not be a viable cognitive enhancer due to its limited availability.
- There are other potent ampakines that are available.
Due to the lack of sufficient data on cx-614 whether from animal or human trials, it is difficult to assume what the effective doses are and what are not. Those who are looking for ampakines for cognitive enhancement should opt for safer and more widely available ampakines such as IDRA-21 and sunifiram.